Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

A programme to evaluate a blood test for early signs of pancreatic cancer has started to recruit volunteers. The Safe-D study ...

Urgent pancreatic cancer tests will be offered on the NHS for those who are most at risk. GPs taking part in the NHS pilot ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

IL-6 blockades with tocilizumab did not improve short-term survival in advanced pancreatic cancer but showed potential ...

OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer ...

Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

Atebimetinib combined with modified chemotherapy achieved a 94% six-month overall survival rate in first-line pancreatic cancer patients, surpassing the typical 67% with standard treatment. The ...